Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. - Wikidata - awgldk - TriplyDB

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

http://www.wikidata.org/entity/Q35164078

about

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases Chemotherapy for brain metastases from small cell lung cancer Whole brain radiotherapy for the treatment of multiple brain metastases Clinical practice guideline on the optimal radiotherapeutic management of brain metastases Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy Combining radiotherapy with sunitinib: lessons (to be) learned Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Motexafin gadolinium in the treatment of brain metastases Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects Resection versus radiosurgery for patients with brain metastases.EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study Whole brain radiotherapy with radiosensitizer for brain metastases Current management of metastatic brain disease Radiation therapy for brain metastases in breast cancer patients.Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.Predicting compliance and survival in palliative whole-brain radiotherapy for brain metastases.Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.Synthesis and anticancer properties of water-soluble zinc ionophores.Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastases Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors.Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases Cognition in patients with newly diagnosed brain metastasis: profiles and implications.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Six degrees of separation: the oxygen effect in the development of radiosensitizers.A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.Real-time pretreatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933."Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.The biology of brain metastases-translation to new therapies Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.The molecular biology of brain metastasis Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

P2860

Q24200466-A3A28415-ECC1-4B6F-B6F5-444D9CDA9641 Q24202771-B5386FBF-8063-4F2E-BD41-666662004CE6 Q24245002-A26991B0-B423-4B09-8978-0105F2261415 Q24798845-22E3C30B-5313-4004-8083-C84FC8263BA1 Q26740191-F4271133-33D4-4875-A5D5-1EF29B8C51F0 Q26800587-15928425-AF5D-4D9B-9B6D-1A3F74A69C06 Q26800626-7B034886-385A-41FE-9086-B7AEFEE03B19 Q27310843-48CE8BD2-76E8-4507-AE15-90A7B0876DA0 Q28285963-696CC6F4-3600-4C0B-8913-4B842A3C1293 Q30239901-687B838B-0F60-4A7F-80C4-11BED90BB1D8 Q30356590-FAD9E2D0-9426-46E1-8817-55CE9EFC241E Q30858160-E4312F53-AA11-4DBC-B2C6-73D7BF39ABF0 Q31097790-CC98F066-8906-400E-8829-E75B7339AE9D Q33249813-2CD0AF65-CDD0-42FF-A969-BAB075370DB7 Q33365043-C87D85AA-E619-49B2-9F13-05AAA2F11A4F Q33397865-B703074B-A0A3-49B1-82D0-BAF6CBAA1489 Q33475484-DEAB5FE0-35A0-42C6-9DA9-272F077D378F Q33574565-8F9DC30D-1E7B-4946-BD62-C2A06236DF32 Q33599135-CD067415-AB46-4809-969F-9A9F840656DF Q33599167-94EC0E48-4054-4EA7-BED4-CD956B69A84D Q33755725-5D3803D8-B19F-43FE-A9E2-C7C13EEDB437 Q33975357-68FBE1E6-14B4-416C-A716-07FB163C131C Q34134011-666387EE-E31D-4C02-999C-DF8707A28916 Q34308963-171A83E4-EAEB-4042-8652-E5AC6E9908C4 Q34551025-69D3A201-599F-485E-A820-157C612474A9 Q34551766-256FE9E6-1BB1-4D8E-9EC2-847B07115CBF Q34566891-A86731C3-7019-4097-B550-E0A171AF19F2 Q34570658-152CD70F-1886-4B76-BA8D-C72A860543EA Q34872345-B2C6B011-0009-46E3-9879-EF7838524898 Q34886787-608FC318-8BD3-461D-9CC7-D9ACC4E2A88A Q34972626-BB41D420-66ED-4315-96AD-4AC5E95BC575 Q34992513-B3EB4FF3-EC47-468B-B5C8-9B06A0F0FACE Q35116798-E4FBE745-D004-408C-8213-7EAE380A217A Q35207344-964445EF-3E57-455B-A85A-10F4E50B504B Q35542459-0F8D25C6-45F5-4E63-9D69-34F11E76A639 Q35570245-9B3235D6-00E9-4874-8D01-A587039F6443 Q35676602-A05AA690-F43C-4DC3-9247-7E552D4AF6E3 Q35845236-F2495B20-54CE-41C6-912D-A8616C9231D1 Q35864968-886FFD25-5A09-4541-99F8-D0ED8724D0E1 Q35885064-1CE9AC7C-76D6-4196-8549-A6FCAAD0EDDD

P2860

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

http://www.wikidata.org/entity/Q35164078

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

name

Survival and neurologic outcom ...... n therapy in brain metastases.

@ast

Survival and neurologic outcom ...... n therapy in brain metastases.

@en

type

label

Survival and neurologic outcom ...... n therapy in brain metastases.

@ast

Survival and neurologic outcom ...... n therapy in brain metastases.

@en

prefLabel

Survival and neurologic outcom ...... n therapy in brain metastases.

@ast

Survival and neurologic outcom ...... n therapy in brain metastases.

@en

P1433

Q35164078-795A42DC-DB90-47A0-BF85-C5A30A518CC7

P1476

Q35164078-56B9070B-25AE-4DC2-8C32-DFBF9945F52E

P2093

Q35164078-42A814A2-5A3B-44B6-BB00-6F2F587F64B2

Q35164078-6EBED8B9-BDA2-406D-92AF-2BFD6D777454

Q35164078-75CD2449-EFCA-4B81-B382-E13D2614A41C

Q35164078-7959E5F2-5D0E-4407-94D6-B6A280F6F946

Q35164078-8507AF2F-5122-4311-BB54-841E985A4726

Q35164078-86521ECD-2A8D-4546-B7B0-644E33733504

Q35164078-9526D4E9-48A1-410C-91F5-319D8C6E94D5

Q35164078-9B43F393-FB8C-45B0-A9F9-EDFB709A5C1E

Q35164078-A383CE24-E78A-4849-A6DD-1163BF1E0EC1

Q35164078-AB1BE797-1DDB-479B-8A72-DDD779AA8DEC

P304

Q35164078-2817D095-769A-4636-877A-760B890CD2C5

P31

Q35164078-19DD21A2-B426-471D-BE8D-4B664C7A8B9E

P356

Q35164078-D6DF5CE6-0E92-4729-8D31-3249A2CA38FE

P407

Q35164078-721133D7-C906-4F94-9F7C-1B56918F4632

P433

Q35164078-20862BB9-4F8E-48D0-9A27-6DEBA0A3F5AC

P478

Q35164078-79C5463D-6DAC-4803-AFFF-9E587395B6A1

P50

Q35164078-43840657-3E2A-451E-8117-3D031C11ABF3

Q35164078-CE300B7E-FD1E-4E94-8E07-0EFF9391B78E

P577

Q35164078-0161FD6A-C204-4868-A92F-D2740F58C5C1

P698

Q35164078-CAB07046-D43D-49F8-975A-8EC45FE17A65

P921

Q35164078-DA56DBE2-B763-4043-942C-7D5AB3FDDCA0

P356

JCO.2003.12.122

P1433

Journal of Clinical Oncology

P1476

Survival and neurologic outcom ...... n therapy in brain metastases.

@en

P2093

Andrea Bezjak

http://www.w3.org/2001/XMLSchema#string

Aroor Rao

http://www.w3.org/2001/XMLSchema#string

C H J Terhaard

http://www.w3.org/2001/XMLSchema#string

Christopher Schultz

http://www.w3.org/2001/XMLSchema#string

Jennifer Smith

http://www.w3.org/2001/XMLSchema#string

John Suh

http://www.w3.org/2001/XMLSchema#string

Luis Souhami

http://www.w3.org/2001/XMLSchema#string

Mark Leibenhaut

http://www.w3.org/2001/XMLSchema#string

Markus F Renschler

http://www.w3.org/2001/XMLSchema#string

Patrick Rodrigus

http://www.w3.org/2001/XMLSchema#string

P304

2529-2536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.12.122

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12829672

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy